QuatCy-I2 and MHI-I2 in Photodynamic Therapy

Sopida Thavornpradit; Syed Muhammad Usama; G Kate Park; Jason Dinh; Hak Soo Choi; Kevin Burgess

doi:10.1021/acsmedchemlett.1c00640

QuatCy-I₂ and MHI-I₂ in Photodynamic Therapy

ACS Med Chem Lett. 2022 Feb 18;13(3):470-474. doi: 10.1021/acsmedchemlett.1c00640. eCollection 2022 Mar 10.

Authors

Sopida Thavornpradit¹, Syed Muhammad Usama¹, G Kate Park², Jason Dinh², Hak Soo Choi², Kevin Burgess¹

Affiliations

¹ Department of Chemistry, Texas A&M University, Box 30012, College Station, Texas 77842, United States.
² Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.

Abstract

MHI-I₂ (1) and QuatCy-I₂ (2) were compared in terms of properties important for early-stage photodynamic therapy preclinical candidates. Thus, experiments were performed to monitor dark cytotoxicities, light/dark cytotoxicity ratios, selectivity of localization in tumors over other organs, and clearance from the plasma.

Abstract

Grants and funding